Introduction
============

COPD is a major cause of morbidity and mortality, leading to an estimated 3.1 million deaths globally in 2012.[@b1-copd-12-2179] Although symptoms and exacerbation rate have been added to our assessment system of COPD,[@b2-copd-12-2179] spirometry remains an important tool in assessing severity and prognosis in this disease. Changes in the forced expiratory volume in 1 second (FEV~1~) are still the best indicator of disease progression and the risk of dying from COPD.[@b2-copd-12-2179],[@b3-copd-12-2179] Yet, on an individual level, FEV~1~ is an unreliable marker of morbidity, especially in early disease,[@b4-copd-12-2179]--[@b6-copd-12-2179] and there is a need to identify alternative objective tests that can aid in stratifying the risk of further patient deterioration.

Patients who exhibit tidal expiratory flow limitation (EFL~T~) might be such a subgroup. EFL~T~ occurs when increases in driving pressure fail to increase expiratory flow during resting tidal breathing and is most often seen in patients with severe COPD,[@b7-copd-12-2179],[@b8-copd-12-2179] although it can occur with only moderate airway obstruction. Previous studies of EFL~T~ in COPD have focused on its association with operating lung volume, exercise tolerance,[@b9-copd-12-2179],[@b10-copd-12-2179] and its relation to breathlessness.[@b11-copd-12-2179]--[@b13-copd-12-2179] It is not known whether EFL~T~ can provide longer-term prognostic information in COPD.

EFL~T~ can be detected by the forced oscillation technique (FOT).[@b14-copd-12-2179],[@b15-copd-12-2179] When peripheral airways collapse on expiration, oscillatory pressure signals are prevented from reaching the alveoli. As this happens, the oscillatory compliance is reduced. Consequently, expiratory reactance (Xrs~exp~) becomes more negative than the inspiratory reactance (Xrs~insp~), leading to a within-breath reactance difference (ΔXrs). In the absence of EFL~T~, reactance measured in inspiration and in expiration is almost identical. The within-breath reactance difference (ΔXrs) cut-off of 0.28 kPa·s·L^−1^ has been defined and validated to identify flow-limited breaths.[@b14-copd-12-2179],[@b15-copd-12-2179] EFL~T~ is not only linked to dyspnea in COPD,[@b11-copd-12-2179],[@b16-copd-12-2179] but also to COPD exacerbations, where ΔXrs have been found to increase at the onset of COPD exacerbations and decrease when the exacerbation resolves.[@b17-copd-12-2179]

In this study, we used forced oscillation technique to define EFL~T~ in 425 patients with COPD. We hypothesized that the presence of EFL~T~, assessed by increased mean ΔXrs $(\Delta\overline{\text{Xrs}})$, would relate to changes in 6MWD, the risk of COPD exacerbations, and, possibly, mortality. We explored these hypotheses using baseline $\Delta\overline{\text{Xrs}}$ as a predictor for future events. Patients with COPD with abnormally high $\Delta\overline{\text{Xrs}}$, both above the upper limit of normal (ULN) and above the established threshold of EFL~T~, were investigated to determine whether they differed from those without evidence of tidal expiratory flow limitation.

Methods
=======

Study design and patients
-------------------------

The current data derive from the Bergen cohort of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study,[@b18-copd-12-2179] with additional patients enrolled from our clinical catchment area. Written informed consent was obtained from all study subjects. The study was approved by the regional ethics committee, REK vest (REK 165.08), and performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines ([ClinicalTrials.gov](http://ClinicalTrials.gov); No: NTC00292552; [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)).[@b39-copd-12-2179]

Inclusion criteria for patients with COPD were: age 40--75 years, FEV~1~ \<80% predicted, FEV~1~/FVC \<0.7, and a smoking history of ≥10 pack-years. Study patients were evaluated every 6 months for 3 years with an additional visit at 3 months after baseline, totaling eight visits. The American Thoracic Society-Division of Lung Disease (ATS-DLD-78) questionnaire and the modified Medical Research Council dyspnea scale score (mMRC) were used to record respiratory symptoms.[@b19-copd-12-2179],[@b20-copd-12-2179]

Post-bronchodilator spirometry and oscillatory lung mechanics during tidal breathing were performed after inhalation of 0.4 mg salbutamol (GlaxoSmithKline, Ventolin, London, UK) according to American Thoracic Society/European Respiratory Society (ATS/ERS) international standards at each visit using a Jaeger MasterScope CT Impulse Oscillation System (Jaeger, Hoechberg, Germany).[@b21-copd-12-2179],[@b22-copd-12-2179] Local reference values were used to determine the FEV~1~% predicted.[@b23-copd-12-2179] The FOT measurements were performed with the patient seated, cheeks supported, and wearing a nose clip. We performed three continuous measurements of 30 seconds, totaling 90 seconds of tidal volume breathing. Acceptability of measurements was determined using the ERS 2003 task force recommendations.[@b22-copd-12-2179]

$\Delta\overline{\text{Xrs}}$ reactance was averaged over the 90-second sample, containing several breaths, and was calculated as follows: $\Delta\overline{\text{Xrs}} = \text{mean}$ Xrs~insp~ at 5 Hz -- mean Xrs~exp~ at 5 Hz. Two cut-offs were investigated: the ULN defined as the 97.5th percentile of healthy controls in the Bergen cohort of the ECLIPSE study ($\Delta\overline{\text{Xrs}} = 0.09\ \text{kPa} \cdot s \cdot L^{- 1}$; [Figure S1](#SD1-copd-12-2179){ref-type="supplementary-material"}),[@b13-copd-12-2179] and at the established EFL~T~ defining threshold for within-breath reactance, 0.28 kPa·s·L^−1^, derived from single-breath analysis.[@b14-copd-12-2179],[@b15-copd-12-2179] To illustrate the variability of our multiple-breath measurement, $\Delta\overline{\text{Xrs}}$ was plotted against time in a subset of the patients defined EFL~T~ at baseline with complete visits (N=20).

Study outcomes
--------------

Distance walked during the 6-minute walk test (6MWT) was used to assess exercise performance. The 6MWT was supervised by a trained technician and performed in a 30-m, straight hospital corridor according to agreed standards at baseline and at the end of the study, at the 3-year visit.[@b24-copd-12-2179]

Exacerbations were defined as a worsening of respiratory symptoms over 2 days or more that required systemic corticosteroids or antibiotics, alone or in combination ("moderate exacerbations"), or exacerbations resulting in hospitalization ("severe exacerbations"). Assessment of exacerbations was performed retrospectively by the study physician at the half-yearly visits, over the 3-year study period.

Mortality statistics were retrieved on August 25, 2011, approximately 5 years after the conclusion of the baseline visit by checking vital status in our local patient file system, which is linked to the Norwegian Causes of Death Registry. The Causes of Death Registry includes deaths of all residents, regardless of whether they die in Norway or abroad, and is assumed to have information on \>98% of all deaths.[@b25-copd-12-2179]

Statistics
----------

IBM SPSS version 22, Stata 13.1, and R 3.2.3 GUI 1.66 were used for different aspects of statistical analyses. Data are presented as mean ± standard deviation, median (quartiles), mean (95% confidence interval), and absolute count or percentage. Means were compared using independent samples *t*-tests, paired samples *t*-tests, or Mann--Whitney *U* test when appropriate.

Patients were categorized into three groups according to $\Delta\overline{\text{Xrs}}$: normal, ≥ ULN \< EFL~T~, and ≥ EFL~T~ at baseline. We report the change in the 6-minute walk distance in these three groups from baseline to the 3-year visit in notched boxplots. Differences in walking distance between baseline and the end of the study were compared using paired samples *t*-test, grouping the patients according to the $\Delta\overline{\text{Xrs}}$ and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade.[@b2-copd-12-2179]

The rate of exacerbations in the three groups was analyzed as suggested by Keene et al using a negative binomial regression model, accounting for the yearly variability among test subjects in the exacerbation rate over the 3-year study period, adjusting for FEV~1~, age, sex, and a binary classifier identifying frequent exacerbators in the year prior to inclusion.[@b26-copd-12-2179] Parameter effects of the baseline explanatory variables are reported as annual rate ratios (RRs), 95% confidence interval (CI), and *P*-values. Moderate and severe exacerbations requiring hospitalization were also investigated on the basis of the occurrence of $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ at baseline by time to first event analysis. Groups were compared using a log-rank test. Results are displayed as 1-minus-survival plots.

Survival analysis was performed with Kaplan--Meier survival analysis, comparing distributions with the log-rank test, grouping patients by the occurrence of $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ at baseline, and by dichotomizing FEV~1~ at 50% of that predicted.

Results
=======

Baseline characteristics
------------------------

In this population of patients with COPD, 60% were men and had moderate to very severe airway obstruction. Women were, on average, 2 years younger and had lower tobacco exposure ([Table S1](#SD2-copd-12-2179){ref-type="supplementary-material"}); 50% of patients with COPD had normal $\Delta\overline{\text{Xrs}}$, 31% were classified as being abnormal with $\Delta\overline{\text{Xrs}} \geq \text{ULN} < \text{EFL}_{T}$, and 18% had $\Delta\overline{\text{Xrs}}$ above the threshold of EFL~T~ ([Table 1](#t1-copd-12-2179){ref-type="table"}). From the normal to the abnormal group, lung function worsened with a decline in FEV~1~ and FVC, and an increase in body mass index (BMI) and mMRC. This difference was most marked between the normal and EFL~T~ group. For IC, we only found a significant difference between the normal and the EFL~T~ group.

$\Delta\overline{\text{Xrs}}$ was not a stable measurement. Many patients defined as EFL~T~ at baseline fell below the EFL~T~ threshold during the course of the study ([Figure 1](#f1-copd-12-2179){ref-type="fig"}). Six percent of the consequent $\Delta\overline{\text{Xrs}}$ measurements were found to be normal; 23% of the patients dropped out of the study before the final visit, the main reason being death during the study period ([Table 2](#t2-copd-12-2179){ref-type="table"}).

Relationship of EFL~T~ to study outcomes
----------------------------------------

$\Delta\overline{\text{Xrs}}$ was as poorly correlated with baseline 6-minute walking distance as FEV~1~ ([Figure 2A and B](#f2-copd-12-2179){ref-type="fig"}). On a group level, 6MWD declined with increasing $\Delta\overline{\text{Xrs}}$, being 455 m in the normal, 410 m in the abnormal, and 363 m in the EFL~T~ group ([Table 1](#t1-copd-12-2179){ref-type="table"}). In patients who completed both the baseline and the final visit, changes in 6MWD were compared. No significant change between the baseline and the final 3-year visit was seen in the 6MWD of patients with normal $\Delta\overline{\text{Xrs}}$. Patients with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ declined by a mean of 37 m (95% CI 15--58), *P*=0.001, and patients with EFL~T~ declined by 63 m (95% CI 31--95), *P*\<0.001 ([Figure 2C](#f2-copd-12-2179){ref-type="fig"}). Grouping by GOLD grade produced similar boxplots. GOLD 2 patients remained stable whereas a significant decline was seen in GOLD 3--4 grades ([Figure 2D](#f2-copd-12-2179){ref-type="fig"}).

A total of 1,289 moderate to severe exacerbations were recorded throughout the study. By negative binomial regression, estimated annual exacerbations rates were 0.7 in patients with normal $\Delta\overline{\text{Xrs}}$, 1.3 in patients with COPD with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$, and 1.6 in patients with EFL~T~. Annual exacerbation RR compared to the normal group was 1.28 for ULN patients and 1.30 for EFL~T~ patients ([Table 3](#t3-copd-12-2179){ref-type="table"}). A time to first exacerbation analysis was performed in patients with COPD with and without evidence of $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ at baseline. Significant differences were found in both time to first exacerbation (*P*=0.009) and in time to first hospitalization (*P*=0.017; [Figure 3A](#f3-copd-12-2179){ref-type="fig"}). Median time to first moderate or severe exacerbation was 76 weeks in patients with COPD with normal $\Delta\overline{\text{Xrs}}$, compared with only 55 weeks in COPD patients with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ at baseline ([Table 4](#t4-copd-12-2179){ref-type="table"}). The time until 25% of the patients were hospitalized was 126 weeks in patients with normal $\Delta\overline{\text{Xrs}}$ and 72 weeks in patients with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$.

Mortality
---------

At the 5-year census, 72 (17%) of the 425 patients with COPD had died. Deaths were significantly more frequent in patients with ≥ ULN than in patients with normal $\Delta\overline{\text{Xrs}}$, but not significantly different between the ≥ ULN and the EFL~T~, groups ([Table 1](#t1-copd-12-2179){ref-type="table"}). Mortality was higher in patients with FEV~1~ \<50% ([Figure 4](#f4-copd-12-2179){ref-type="fig"}). The difference in mortality between patients with $\Delta\overline{\text{Xrs}}$ in the normal range and ≥ ULN was driven by increased mortality in patients with FEV~1~ \>50% ([Figure 4](#f4-copd-12-2179){ref-type="fig"}). Mortality was 17% in $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ patients with FEV~1~ \>50%, compared to 5% in patients with normal ΔXrs (*P*\<0.001; [Figure 4](#f4-copd-12-2179){ref-type="fig"}). Mortality in patients with ΔXrs ≥ ULN was similar to what was found in patients with COPD with much more advanced airway obstruction.

Discussion
==========

Using data from the ECLIPSE study, we investigated associations between increased $\Delta\overline{\text{Xrs}}$ at the ULN and at the threshold of EFL~T~ with decline in 6MWD, risk of later exacerbations, and all-cause mortality. No change in 6MWD was found in patients with COPD with $\Delta\overline{\text{Xrs}}$ in the normal range. All patients with COPD with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ deteriorated significantly in 6MWD. Patients with COPD with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ had increased risk for both moderate and severe exacerbations, and, in the patients with only moderate airway obstruction, FEV~1~ \>50%, a significantly higher mortality. This study Xrs demonstrates that $\Delta\overline{\text{Xrs}}$ provides valuable extra information in addition to FEV~1~ when characterizing the effects of small-airway obstruction on key COPD outcomes.

We defined the ULN at the 97.5th percentile of healthy controls included in our study. Data describing the control group have previously been published.[@b13-copd-12-2179],[@b18-copd-12-2179] The FOT threshold identifying a single flow-limited breath has been defined when within-breath reactance was \>0.28 kPa·s·L^−1^.[@b14-copd-12-2179],[@b15-copd-12-2179] We interpreted our continuous spectrum measurements performed over several breaths as showing evidence of flow limitation when measurements between the ULN and the threshold of EFL~T~ were found. These borderline measurements are thought to represent a mixture of normal and flow-limited breaths.

Exercise limitation is extremely common in COPD, and even small decreases in the 6MWD over time identify patients with increased risks of dying.[@b27-copd-12-2179] When EFL~T~ is present, patients can only increase their minute ventilation during exercise by increasing breathing frequency or by dynamic hyperinflation, allowing end-expiratory lung volume to rise.[@b28-copd-12-2179] Dynamic hyperinflation can be induced by self-paced walking exercise. This is usually assessed by changes in operating lung volume.[@b12-copd-12-2179],[@b29-copd-12-2179] We did not measure lung volume during the 6MWT, but reasoned that patients with COPD showing evidence of flow limitation at baseline, either as having $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ or the threshold of EFL~T~, were more likely to have a worse exercise tolerance at the same visit. This was true on a group level. The EFL~T~ group had the lowest 6MWD, but neither FEV~1~ % predicted nor any cut-off level of $\Delta\overline{\text{Xrs}}$ could identify patients with COPD with a short walking distance (\<350 m), as proposed by Spruit et al.[@b30-copd-12-2179] No significant decline was seen in patients with $\Delta\overline{\text{Xrs}}$ in the normal range; in patients with COPD with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ it declined 37 m, and in patients with EFL~T~, it declined by 63 m. The minimal clinically important difference on an individual level has been suggested to be 30 m in an ERS/ATS systematic review;[@b31-copd-12-2179] consequently, the differences seen over time between our subgroups defined by $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ and EFL~T~ are likely to be clinically important.

Exacerbation and hospitalization rates at our site were similar to those reported in the completed ECLIPSE study and in the TORCH study.[@b32-copd-12-2179],[@b33-copd-12-2179] By negative binomial regression, the $\Delta\overline{\text{Xrs}} \geq \text{cut-offs}\ \text{ULN}$ and EFL~T~ were both significant predictors for higher rates of exacerbations with very similar RR, demonstrating that the increased risk of exacerbations by EFL~T~ is identified already at ULN. In the time to first event analysis of patients with $\Delta\overline{\text{Xrs}} \geq \text{ULN}$, we found a shorter time to first exacerbation and a shorter time to first hospitalization than that of the COPD patients with $\Delta\overline{\text{Xrs}}$ in the normal range. A previous study on hospitalized patients showed that many, but not all, have FOT-defined EFL~T~ during a COPD exacerbation.[@b17-copd-12-2179] FOT measurements performed during hospitalized COPD exacerbations show that $\Delta\overline{\text{Xrs}}$ measurements improve during resolution of an exacerbation, although many patients remain EFL~T~ at discharge.[@b17-copd-12-2179] At present, there is a shortage of readily measurable biomarkers that can predict the risk of future exacerbations. Our data suggest that, after adjusting for lung function and exacerbation history, EFL~T~ measurement can identify patients who are more likely to develop exacerbations. Further prospective studies to confirm these observations and explore their mechanism are merited.

Patients with COPD with an FEV~1~ \>50% predicted and evidence of EFL~T~, defined as baseline ΔXrs ≥ ULN, had significantly higher risk of dying within the 5-year follow-up. Similar associations were not found in the patients with more advanced airway obstruction and FEV~1~ \<50%. However, COPD is a complex, heterogeneous disease, and respiratory impairment is associated with higher incidence of comorbidities, such as hypertension, cardiovascular disease, and diabetes.[@b34-copd-12-2179] If there is an association between $\Delta\overline{\text{Xrs}}$ and mortality, the higher risk of adverse outcomes associated with comorbid disease could mask such an association with advanced disease. Although the association between death and $\Delta\overline{\text{Xrs}}$ was highly significant, this sub-analysis should be interpreted with caution due to the relatively small number of deaths in patients with FEV~1~ \>50% predicted ([Table 1](#t1-copd-12-2179){ref-type="table"}).

There are certain limitations of this study. The FOT threshold identifying a single flow-limited breath has been defined at $\Delta\overline{\text{Xrs}} > 0.28\ \text{kPa} \cdot s \cdot L^{- 1}$.[@b14-copd-12-2179],[@b15-copd-12-2179] It is not known whether the use of this threshold may lead to different results when applied to values measured over a continuous spectrum of several breaths. Previously published data show that the end-expiratory lung volume varies from breath-to-breath, affecting the prevalence of EFL~T~.[@b8-copd-12-2179],[@b15-copd-12-2179] Although the prevalence of EFL~T~ increased as the FEV~1~% predicted declined, not all patients with very severe airway obstruction were found to have EFL~T~. In previous studies on elderly and COPD with the NEP technique, higher prevalence of EFL~T~ have been reported than in the present study.[@b11-copd-12-2179],[@b35-copd-12-2179],[@b36-copd-12-2179] Different inclusion criteria and differences in sensitivity between the NEP and the FOT technique, together with the possibility that in borderline patients the application of a NEP per se could lead to development of EFL~T~, are likely explanations. The wide reference range of FEV~1~ inevitably may also lead to an overestimation of the suspected lung function decline in many patients.[@b23-copd-12-2179]

As previously noted, EFL~T~ varies between breaths in many patients with COPD and varies with repeat testing, likely reflecting differences in the end-expiratory lung volume on different test days.[@b13-copd-12-2179] Physiological variability in these measurements might require the repetition of this test in different periods to increase the sensitivity of our test. Despite this limitation, important relationships related to the presence of tidal flow limitation were seen, even when the data were controlled for severity of airflow obstruction measured by FEV~1~. The data reflect results from the largest recruiting center in the ECLIPSE study, in which patients were carefully characterized using standardized methodologies including oscillatory mechanics.[@b18-copd-12-2179],[@b37-copd-12-2179]

Conclusion
==========

Consistent differences in clinically relevant outcomes were found, such as exercise capability, exacerbations, hospitalizations, and death in COPD patients with baseline $\Delta\overline{\text{Xrs}}$ beyond the ULN. This is below the established threshold for EFL~T~. Our data support previous studies showing that patients with EFL~T~ have worse lung mechanics than is evident from FEV~1~ measurement alone.[@b11-copd-12-2179],[@b38-copd-12-2179] The present study suggests that evidence of EFL~T~, measured during tidal breathing in an effort-independent fashion, can identify a subgroup of COPD patients with worse clinical outcomes.

Supplementary materials
=======================

###### 

Scatterplot of $\Delta\overline{\text{Xrs}}$ plotted against FEV~1~ % predicted in healthy controls (N=229). Mean represented by the solid line. The dashed line represents the 97.5th percentile, the upper limit of normal (ULN).

###### 

Baseline characteristics in men and women (N=425)

  Subject characteristics                                                Total         Men           Women         *P*-value
  ---------------------------------------------------------------------- ------------- ------------- ------------- -----------
  Subjects (n)                                                           425           254           171           
  Age (years)                                                            63 (7)        64 (7)        62 (7)        0.014
  BMI kg/m^2^                                                            25 (5)        26 (5)        25 (6)        ns
  Pack-years (years)                                                     41 (23)       45 (24)       33 (18)       \<0.001
  mMRC                                                                   1.6 (1, 2)    1.6 (1, 2)    1.7 (1, 2)    ns
  FEV~1~ (L)                                                             1.5 (0.5)     1.6 (0.6)     1.3 (0.4)     \<0.001
  FEV~1~ (%)                                                             46 (14)       45 (14)       48 (13)       0.007
  FVC (L)                                                                3.3 (0.9)     3.7 (0.8)     2.6 (0.6)     \<0.001
  $\Delta\overline{\text{Xrs}} > (\ \text{kPa} \cdot s \cdot L^{- 1})$   0.14 (0.17)   0.13 (0.14)   0.16 (0.20)   ns

**Note:** Data presented as mean (standard deviation) unless otherwise stated.

**Abbreviations:** ULN, upper limit of normal 0.09 kPa·s·L^−1^; EFL~T~, tidal expiratory flow limitation; BMI, body mass index; Pack-years, packs of 20 cigarettes smoked per day × years as a smoker; Frequent exacerbators, percentage with ≥2 exacerbations the year the prior to inclusion; mMRC, modified Medical Research Council dyspnea scale score -- mean (quartiles); FEV~1~, forced expiratory volume in 1 second; FEV~1~ (%), FEV~1~ percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; $\Delta\overline{\text{Xrs}}$, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.
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![Timeplot illustrating the variability of $\Delta\overline{\text{Xrs}}$ measurements (splines) over the course of the study shown in the first 20 patients with COPD with complete visits, defined as having EFL~T~ at baseline $(\Delta\overline{\text{Xrs}} > 0.28\ \text{kPa} \cdot s \cdot L^{- 1})$. The dotted line is set at 0.09 kPa·s·L^−1^, the upper limit of normal and the solid line at EFL~T~.](copd-12-2179Fig1){#f1-copd-12-2179}

![(**A**) Six-minute walk distance (6MWD) in patients with COPD (N=388) at different levels of FEV~1~% predicted (**A**) and $\Delta\overline{\text{Xrs}}$ (**B**) at baseline. Dotted lines set at 350 m (horizontal) and at $\Delta\overline{\text{Xrs}} > 0.09\ \text{kPa} \cdot s \cdot L^{- 1}$, upper limit of normal (ULN), and $\Delta\overline{\text{Xrs}} > 0.28\ \text{kPa} \cdot s \cdot L^{- 1}$, the threshold for tidal expiratory flow limitation (EFL~T~). The solid lines represent the regression lines. (**C**) 6MWT at baseline and the 3-year visit presented by notchplots with quartiles, 95% central range and outliers among COPD patients of GOLD II--IV grades and categorized according to $\Delta\overline{\text{Xrs}}$ (**D**) as normal (white), below EFL~T~, but above ULN (light gray), and \> EFL~T~ threshold (gray). Non-overlapping notched areas are likely to represent significant differences between groups. Solid lines are drawn between the mean 6MWD at baseline and the 3-year visit.](copd-12-2179Fig2){#f2-copd-12-2179}

![Time to first moderate or severe exacerbation (**A**) and to the first hospitalization (**B**) in COPD patients with $\Delta\overline{\text{Xrs}}$ measurements above the upper limit of normal (ULN), 0.9 kPa·s·L^−1^ (solid line), and below the ULN at the baseline visit. Dashed line at 25%.](copd-12-2179Fig3){#f3-copd-12-2179}

![Kaplan--Meier survival curves in COPD patients with normal $\Delta\overline{\text{Xrs}}$ and in COPD patients with $\Delta\overline{\text{Xrs}}$ measurements above the upper limit of normal (ULN). Test of equality of survival distributions was performed using log-rank test.](copd-12-2179Fig4){#f4-copd-12-2179}

###### 

Baseline characteristics in COPD patients with different levels of $\Delta\overline{\text{Xrs}}$ (N=425)

  Subject characteristics                                                        Normal                                                                                                Abnormal                                                                                                 EFL~T~
  ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Subjects (n)                                                                   213 (50%)                                                                                             134 (32%)                                                                                                78 (18%)
  Women                                                                          40%                                                                                                   36%                                                                                                      49%
  Age (years)                                                                    63 (7)                                                                                                64 (7)                                                                                                   63 (6)
  BMI kg/m^2^                                                                    24 (5)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}       26 (5)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}          28 (6)[d](#tfn5-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}
  Pack-years (years)                                                             40 (24)                                                                                               43 (22)                                                                                                  39 (22)
  Frequent exacerbators (%)                                                      13%                                                                                                   20%                                                                                                      35%
  mMRC                                                                           1.2 (0, 2)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}   1.8 (0.25, 2)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}   2.3 (1, 2)[d](#tfn5-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}
  FEV~1~ (L)                                                                     1.7 (0.5)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}    1.3 (0.5)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}       1.1 (0.4)[d](#tfn5-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}
  FEV~1~ (%)                                                                     52 (11)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}      42 (12)[c](#tfn4-copd-12-2179){ref-type="table-fn"}                                                      38 (13)[d](#tfn5-copd-12-2179){ref-type="table-fn"}
  FVC (L)                                                                        3.5 (0.9)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}    3.2 (0.8)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}       2.8 (0.9)[d](#tfn5-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}
  IC (L)                                                                         2.6 (0.8)[d](#tfn5-copd-12-2179){ref-type="table-fn"}                                                 2.5 (0.7)                                                                                                2.3 (0.7)[d](#tfn5-copd-12-2179){ref-type="table-fn"}
  IC (%)                                                                         88 (19)                                                                                               85 (20)                                                                                                  84 (21)
  6MWD (meters)                                                                  455 (102)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}    410 (109)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}       363 (110)[d](#tfn5-copd-12-2179){ref-type="table-fn"},[e](#tfn6-copd-12-2179){ref-type="table-fn"}
  Estimated exacerbations per year[a](#tfn2-copd-12-2179){ref-type="table-fn"}   0.7                                                                                                   1.3                                                                                                      1.6
  Deaths[b](#tfn3-copd-12-2179){ref-type="table-fn"}                             25 (12)[c](#tfn4-copd-12-2179){ref-type="table-fn"},[d](#tfn5-copd-12-2179){ref-type="table-fn"}      28 (21)[c](#tfn4-copd-12-2179){ref-type="table-fn"}                                                      18 (23)[d](#tfn5-copd-12-2179){ref-type="table-fn"}

**Notes:** Data presented as mean ± standard deviation unless otherwise stated.

Estimated exacerbation rate by negative binomial model.

Number of deaths at the 5-year census (%). Significant differences at the 5% level are marked as

between normal and abnormal,

between normal and EFL~T~, and

between abnormal and EFL~T~. pack-years: packs of 20 cigarettes smoked per day × years as a smoker; Frequent exacerbators: percentage with ≥2 exacerbations the year the prior to inclusion.

**Abbreviations:** ULN, upper limit of normal 0.09 kPa·s·L^−1^; EFL~T~, tidal expiratory flow limitation; BMI, body mass index; mMRC, modified Medical Research Council dyspnea scale score -- mean (quartiles); FEV~1~, forced expiratory volume in 1 second; FEV~1~ (%), FEV~1~ percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; $\Delta\overline{\text{Xrs}}$, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.

###### 

Deaths and dropouts during the 3-year study period (N=96)

  Reason                                                 N    \%
  ------------------------------------------------------ ---- ----
  Died                                                   41   10
  FOT not performed at the final visit                   16   4
  Refused further participation                          8    2
  Excluded due to use of oral steroids                   8    2
  Excluded after being diagnosed with pulmonary cancer   5    1
  Other causes                                           18   4
  Total                                                  96   23

**Abbreviation:** FOT, forced oscillation technique.

###### 

Annual rate ratios estimated by negative binomial regression (N=395)

  Baseline explanatory variables                RR     95% CI       *P*-value
  --------------------------------------------- ------ ------------ -----------
  $\Delta\overline{\text{Xrs}}$                                     
   ≥ULN (0.09 kPa·s·L^−1^) and \<EFL~T~         1.28   1.05, 1.55   0.011
   ≥EFL~T~ (0.28 kPa·s·L^−1^)                   1.30   1.05, 1.64   0.009
  FEV~1~ % predicted                            0.07   0.04, 0.14   \<0.001
  Age in decades                                1.36   1.06, 1.34   0.009
  Sex (male)                                    0.85   0.72, 1.00   0.048
  Exacerbation in the year prior to inclusion                       
   ≥2                                           1.99   1.64, 2.41   \<0.001
  Intercept                                     0.98   0.42, 2.27   0.965

**Abbreviations:** RR, estimated rate ratio; 95% CI, confidence interval; ULN, upper limit of normal 0.09 kPa·s·L^−1^; EFL~T~, tidal expiratory flow limitation; FEV~1~, forced expiratory volume in 1 second; FEV~1~ (%), FEV~1~ percentage of predicted.

###### 

Exacerbations, hospitalizations, and deaths in COPD patients with and without $\Delta\overline{\text{Xrs}} \geq \text{ULN}$ at baseline (N=425)

  Parameter                                                   $\Delta\overline{\text{Xrs}} < \text{ULN}$   $\Delta\overline{\text{Xrs}} \geq \text{ULN}$
  ----------------------------------------------------------- -------------------------------------------- -----------------------------------------------
  **Total N**                                                 213                                          212
  N patients (%) with exacerbation                            144 (68%)                                    152 (72%)
   Median time (weeks) to first exacerbation (95% CI)         76 (57, 95)                                  55 (42, 68)
   Log-rank test                                              *P*=0.009                                    
  N patients (%) hospitalized                                 62 (29%)                                     84 (40%)
   Time (weeks) until 25% of the patients were hospitalized   126                                          72
   Log-rank test                                              *P*=0.017                                    
  N dead at 5-year follow-up                                  25 (12%)                                     46 (22%)
   Log-rank test                                              *P*=0.011                                    

**Note:** ULN defined at $\Delta\overline{\text{Xrs}} \geq 0.09\ \text{kPa} \cdot s \cdot L^{- 1}$.

**Abbreviations:** ULN, upper limit of normal 0.09 kPa·s·L^−1^; 95% CI, 95% confidence interval.
